Discover 859 paid clinical trials in Tuscaloosa, Alabama. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 859
Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.
for
Refractory Angina, Coronary Artery Disease
Location: Birmingham AL, Atlanta GA, Cincinnati OH, Durham NC,
Sponsor: XyloCor Therapeutics, Inc.
Sex: All
Age: 18 - 70+
Code: NCT07048808
Phase2, Recruiting
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
Get alerts for new trials in your area by subscribing now
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
for
Relapsing Multiple Sclerosis
Location: Birmingham AL, Cullman AL, Atlanta GA, Knoxville TN,
Sponsor: TG Therapeutics, Inc.
Sex: All
Age: 18 - 65
Code: NCT05877963
Phase3, Recruiting
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
for
Atopic Dermatitis
Location: Birmingham AL, Macon GA, North Little Rock AR,
Sponsor: LEO Pharma
Sex: All
Age: 0 - 11
Code: NCT06311682
Phase3, Recruiting
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
for
Asthma
Location: Birmingham AL, Albany GA, Owensboro KY, Maryville IL,
Sponsor: Enveda Therapeutics
Sex: All
Age: 18 - 70+
Code: NCT07301255
Phase2, Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
for
Relapsing Multiple Sclerosis, Multiple Sclerosis
Location: Birmingham AL, Cullman AL, Huntsville AL, Mobile AL,
Sponsor: TG Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06433752
Recruiting
New
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
for
Cutaneous Lichen Planus
Location: Birmingham AL, New Orleans LA, Indianapolis IN,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT07775924
Phase2, Recruiting
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
for
Atrophic Vaginitis, Vaginal Atrophy,
Location: Birmingham AL, West Columbia SC, Fayetteville NC,
Sponsor: Stratpharma AG
Sex: Female
Age: 18+
Code: NCT05953090
Recruiting
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
for
Atopic Dermatitis
Location: Birmingham AL, North Little Rock AR, Greenville SC,
Sponsor: Pfizer
Sex: All
Age: 2 - 11
Code: NCT06807281
Phase3, Recruiting
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
for
Chronic Inducible Urticaria, Cold Urticaria,
Location: Birmingham AL, Columbus GA, Bowling Green KY,
Sponsor: Celldex Therapeutics
Sex: All
Age: 18+
Code: NCT07266402
Phase3, Recruiting
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
Location: Birmingham AL, Bryant AR, Clarksville IN,
Sponsor: Apollo Therapeutics Ltd
Sex: All
Age: 18 - 65
Code: NCT07599813
Phase2, Recruiting
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
for
Prurigo Nodularis (PN)
Location: Birmingham AL, Indianapolis IN, Mayfield Heights OH,
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Sex: All
Age: 18 - 70+
Code: NCT07236099
Phase2, Recruiting
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
for
Eczema
Location: Birmingham AL, North Little Rock AR, Greenville SC,
Sponsor: Pfizer
Sex: All
Age: 6 - 11
Code: NCT06807268
Phase3, Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
for
Locally Advanced Head and Neck Squamous Cell Carcinoma